Natural Alternatives International Inc NAII
We take great care to ensure that the data presented and summarized in this overview for NATURAL ALTERNATIVES INTERNATIONAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NAII
View all-
Dimensional Fund Advisors LP Austin, TX427KShares$1.8 Million0.0% of portfolio
-
Caldwell Sutter Capital, Inc. Sausalito, CA414KShares$1.75 Million1.11% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny321KShares$1.35 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA243KShares$1.03 Million0.0% of portfolio
-
Morgan Stanley New York, NY170KShares$717,7840.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX126KShares$531,9900.02% of portfolio
-
Geode Capital Management, LLC Boston, MA45.1KShares$190,1610.0% of portfolio
-
Northern Trust Corp Chicago, IL24.4KShares$102,9460.0% of portfolio
-
Empowered Funds, LLC24.1KShares$101,5070.0% of portfolio
-
Cutter & CO Brokerage, Inc.16.7KShares$70,5200.02% of portfolio
Latest Institutional Activity in NAII
Top Purchases
Top Sells
About NAII
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Asia, and internationally. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, packaging and delivery system design, and regulatory review. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.
Insider Transactions at NAII
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 08
2024
|
Guru Ramanathan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+26.67%
|
-
|
Mar 08
2024
|
Laura Kay Matherly Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+23.53%
|
-
|
Mar 08
2024
|
Alan G Dunn Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+8.77%
|
-
|
Mar 08
2024
|
Kenneth Wolf President, COO, & Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+9.41%
|
-
|
Mar 08
2024
|
Mark A Ledoux CEO/Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+9.28%
|
-
|
Mar 08
2024
|
Michael E Fortin Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+17.34%
|
-
|
Mar 07
2024
|
Kenneth Wolf President, COO, & Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,533
-4.96%
|
$32,665
$5.95 P/Share
|
Mar 07
2024
|
Mark A Ledoux CEO/Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
5,777
-3.73%
|
$28,885
$5.95 P/Share
|
Mar 07
2024
|
Michael E Fortin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,319
-10.52%
|
$26,595
$5.95 P/Share
|
Dec 15
2023
|
Mark A Ledoux CEO/Chairman |
SELL
Bona fide gift
|
Direct |
7,500
-4.62%
|
-
|
Mar 07
2023
|
Guru Ramanathan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+33.33%
|
-
|
Mar 07
2023
|
Alan G Dunn Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+8.51%
|
-
|
Mar 07
2023
|
Laura Kay Matherly Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+28.0%
|
-
|
Mar 07
2023
|
Mark A Ledoux CEO/Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
3,206
-1.94%
|
$25,648
$8.86 P/Share
|
Mar 07
2023
|
Mark A Ledoux CEO/Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+8.31%
|
-
|
Mar 07
2023
|
Michael E Fortin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,255
-6.05%
|
$26,040
$8.86 P/Share
|
Mar 07
2023
|
Michael E Fortin Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+16.98%
|
-
|
Mar 07
2023
|
Kenneth Wolf President, COO, & Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,992
-2.22%
|
$23,936
$8.86 P/Share
|
Mar 07
2023
|
Kenneth Wolf President, COO, & Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+8.81%
|
-
|
Nov 01
2022
|
Mark A Ledoux CEO/Chairman |
SELL
Bona fide gift
|
Direct |
7,500
-4.74%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 67.5K shares |
---|
Payment of exercise price or tax liability | 17.6K shares |
---|